Endpoints NewsOriginal article
GSK heads to FDA with recently acquired drug from Nuvalent
Data ReadoutpositiveJideytroPositive
AI Analysis
Summary
GSK announced positive first-line data for Jideytro, an acquired Nuvalent drug, showing 94% response rate in ROS1-positive NSCLC patients and is moving toward FDA submission.
Clinical Trial Data
Phase
1
Primary Endpoint
Met
Outcome Details
94% response rate in first-line ROS1-positive NSCLC treatment
Importance:7/10
Sentiment:
0.75
oncologylung cancerROS1-positiveNSCLCFDA submissionacquisitionclinical data
Read the original article
Published by Endpoints News on September 14, 2026 3:21 PM